APA (7th ed.) Citation

Rigolin, G. M., Olimpieri, P. P., Summa, V., Celant, S., Scarfò, L., Tognolo, L., . . . Russo, P. (2023). Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: A nationwide registry study from the Italian Medicines Agency. Nature Publishing Group.

Chicago Style (17th ed.) Citation

Rigolin, Gian Matteo, et al. Outcomes in Patients with Chronic Lymphocytic Leukemia and TP53 Aberration Who Received First-line Ibrutinib: A Nationwide Registry Study from the Italian Medicines Agency. Nature Publishing Group, 2023.

MLA (9th ed.) Citation

Rigolin, Gian Matteo, et al. Outcomes in Patients with Chronic Lymphocytic Leukemia and TP53 Aberration Who Received First-line Ibrutinib: A Nationwide Registry Study from the Italian Medicines Agency. Nature Publishing Group, 2023.

Warning: These citations may not always be 100% accurate.